Mycophenolsäure (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Mycophenolic Acid, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat autoimmune diseases such as lupus nephritis. GNH USA supplies Mycophenolic Acid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolic Acid is used in the management of immune‑mediated conditions where suppression of lymphocyte activity is required.

Organ transplant rejection: helps prevent graft loss by inhibiting immune response. Lupus nephritis: reduces renal inflammation and proteinuria in systemic lupus erythematosus. Autoimmune vasculitis: controls disease activity by limiting lymphocyte proliferation.

Adverse reactions may occur with Mycophenolic Acid therapy and are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset (nausea, vomiting, diarrhea) - Headache - Elevated liver enzymes - Mild leukopenia - Hypertension - Fatigue

Serious or Rare Side Effects: - Severe infections (e.g., opportunistic infections) - Bone marrow suppression leading to pancytopenia - Progressive renal dysfunction - Reversible posterior leukoencephalopathy syndrome (RPLS) - Severe hypersensitivity reactions - Malignancies such as lymphoma or skin cancer.

Patients receiving Mycophenolic Acid should be monitored closely for safety and efficacy.

Infection risk: monitor for signs of bacterial, viral, or fungal infections. Hematologic monitoring: regular complete blood counts to detect leukopenia or anemia. Renal function: assess serum creatinine and glomerular filtration rate periodically. Hepatic function: check liver enzymes for potential hepatotoxicity. Pregnancy and lactation: avoid use unless benefits outweigh potential risks. Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Mycophenolic Acid may interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption of Mycophenolic Acid. - Azathioprine: additive bone marrow suppression. - Live vaccines: increased risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase drug levels. - CYP3A4 inducers (e.g., rifampicin): may decrease efficacy. - ACE inhibitors or ARBs: may enhance risk of renal impairment.